Related Experiment Video
Updated: Jan 1, 2026

08:39
Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
Published on: September 16, 2020
8.4K
Mitochondrially-targeted treatment strategies
Luiz H M Bozi1, Juliane C Campos1, Vanessa O Zambelli2
1Institute of Biomedical Sciences, University of Sao Paulo, Brazil.
Molecular Aspects of Medicine
|December 24, 2019
Summary
Mitochondrial dysfunction underlies many diseases. This review explores therapeutic strategies targeting mitochondria, including bioenergetics and detoxification, for various pathologies.
Area of Science:
- Biochemistry
- Cell Biology
- Pathology
Background:
- Mitochondrial dysfunction is implicated in inherited mitochondrial diseases (mitochondriopathies).
- It also contributes to diverse conditions like infections, neurodegeneration, diabetes, obesity, and cardiovascular diseases.
- Mitochondria are therefore crucial therapeutic targets.
Purpose of the Study:
- To review mechanisms maintaining mitochondrial functionality.
- To discuss strategies for identifying and validating mitochondrial drug targets.
- To highlight recent preclinical and clinical findings on mitochondrial-targeted therapies.
Main Methods:
- Literature review of mechanisms in mitochondrial homeostasis.
- Analysis of strategies for target identification and validation.
- Survey of recent studies on molecules targeting mitochondrial functions.
Main Results:
- Mitochondria play a central role in numerous pathologies.
- Various strategies exist to target mitochondrial bioenergetics, morphology, number, and detoxification systems.
- Emerging therapies show promise in preclinical and clinical settings.
Conclusions:
- Targeting mitochondrial dysfunction offers a promising therapeutic avenue for a wide range of diseases.
- Further research into mitochondrial mechanisms and targeted interventions is warranted.
- Developing novel therapeutics for mitochondrial-related pathologies is crucial.
More Related Videos
Related Concept Videos
Electron Transport Chain: Complex I and II
18.3K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
18.3K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Targets for Drug Action: Overview
9.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.9K

